Teva gains US patent extension for Azilect
This article was originally published in Scrip
Executive Summary
The US Patent and Trademark Office has determined that a patent covering Teva Pharmaceutical Industries' Parkinson's disease treatment Azilect (rasagiline) is entitled to the full five years of term extension.